CALT (Calliditas Therapeutics AB) Short-Term Debt to Capital

Calliditas Therapeutics generates revenue through the sale of highly specialized medications targeting renal failure and inflammatory processes. Business growth relies on patent licensing and partnerships with global distributors to promote orphan drugs. This chart of current share prices with the 0.00 metric confirms the company's expansion into new markets following the successful launch of Tarpeyo and the development of its therapeutic platform.

Clinical test automation at Calliditas Therapeutics (CALT) reduces operating expenses, which is reflected in the company's short-term leverage history. This indicator relates liabilities with a maturity of up to one year to total equity, measuring the current financial burden. Low values confirm high liquidity and business resilience, while a sharp increase in the curve signals a risk of working capital deficiency.